W Graham E Cooksley

Summary

Affiliation: Queensland Institute of Medical Research
Country: Australia

Publications

  1. ncbi Peginterferon-alpha 2a for the treatment of hepatitis B infection
    W Graham E Cooksley
    Royal Brisbane Hospital, University of Queensland, Brisbane 4029, Australia
    Expert Opin Pharmacother 6:1373-80. 2005
  2. ncbi The importance and benefits of hepatitis A prevention in chronic liver disease patients
    Graham Cooksley
    Clinical Research Center, Royal Brisbane Hospital, Queensland, Australia
    J Gastroenterol Hepatol 19:S17-20. 2004
  3. ncbi Treatment with interferons (including pegylated interferons) in patients with hepatitis B
    W Graham Cooksley
    Department of Medicine, The University of Queensland, Royal Brisbane Hospital, Queensland, Australia
    Semin Liver Dis 24:45-53. 2004
  4. ncbi Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B
    W G E Cooksley
    Royal Brisbane Hospital, Herston, Queensland, Australia
    J Viral Hepat 10:298-305. 2003
  5. ncbi Therapies for viral hepatitis workshop. 2-3 November 2004, Boston, MA, USA
    Graham Cooksley
    Royal Brisbane Hospital Foundation, Clinical Research Centre, H Floor BanCroft Centre, Herston, QLD 4029, Australia
    IDrugs 8:124-6. 2005
  6. ncbi Treatment of hepatitis B with interferon and combination therapy
    W Graham Cooksley
    Department of Medicine, The University of Queensland, C8 Clinical Sciences Building, Royal Brisbane Hospital, Queensland 4029, Australia
    Clin Liver Dis 8:353-70. 2004
  7. ncbi The role of interferon therapy in hepatitis B
    W Graham E Cooksley
    Department of Medicine, University of Queensland, Royal Brisbane Hospital, Brisbane, Queensland, Australia
    MedGenMed 6:16. 2004
  8. ncbi Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection
    Carolyn A Lang
    Center for Diabetes and Endocrine Research, The University of Queensland, Queensland, Australia
    J Pain Symptom Manage 31:335-44. 2006
  9. ncbi The treatment of hepatitis B e antigen-positive chronic hepatitis B with pegylated interferon
    Graham Cooksley
    Clinical Research Centre, Royal Brisbane Hospital Research Foundation, Brisbane, QLD, Australia
    J Hepatol 39:S143-5. 2003
  10. ncbi Does the addition of lamivudine to peginterferon alpha-2a sustain response rates in HBeAg-negative hepatitis B?
    Graham Cooksley
    University of Queensland, Royal Brisbane Hospital, Brisbane, Australia
    Nat Clin Pract Gastroenterol Hepatol 2:12-3. 2005

Detail Information

Publications11

  1. ncbi Peginterferon-alpha 2a for the treatment of hepatitis B infection
    W Graham E Cooksley
    Royal Brisbane Hospital, University of Queensland, Brisbane 4029, Australia
    Expert Opin Pharmacother 6:1373-80. 2005
    ..PEG-IFN-alpha2a could become the treatment of choice in many patients with both HBeAg-positive and HBeAg-negative disease and, in those who fail to respond, consideration could then be given to the use of antiviral agents...
  2. ncbi The importance and benefits of hepatitis A prevention in chronic liver disease patients
    Graham Cooksley
    Clinical Research Center, Royal Brisbane Hospital, Queensland, Australia
    J Gastroenterol Hepatol 19:S17-20. 2004
  3. ncbi Treatment with interferons (including pegylated interferons) in patients with hepatitis B
    W Graham Cooksley
    Department of Medicine, The University of Queensland, Royal Brisbane Hospital, Queensland, Australia
    Semin Liver Dis 24:45-53. 2004
    ..Side effects in all studies have been tolerable. Thus, these observations in chronic HBV infection, whether HBeAg-positive or HBeAg-negative, suggest an important, even primary, role for pegylated interferon therapy...
  4. ncbi Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B
    W G E Cooksley
    Royal Brisbane Hospital, Herston, Queensland, Australia
    J Viral Hepat 10:298-305. 2003
    ..These results indicate that peginterferon alpha-2a (40 kDa) is superior in efficacy to conventional interferon alpha-2a in chronic hepatitis B based on clearance of HBeAg, suppression of HBV DNA, and normalization of ALT...
  5. ncbi Therapies for viral hepatitis workshop. 2-3 November 2004, Boston, MA, USA
    Graham Cooksley
    Royal Brisbane Hospital Foundation, Clinical Research Centre, H Floor BanCroft Centre, Herston, QLD 4029, Australia
    IDrugs 8:124-6. 2005
  6. ncbi Treatment of hepatitis B with interferon and combination therapy
    W Graham Cooksley
    Department of Medicine, The University of Queensland, C8 Clinical Sciences Building, Royal Brisbane Hospital, Queensland 4029, Australia
    Clin Liver Dis 8:353-70. 2004
    ..Selecting patients for treatment and knowing when to treat them is as important as knowing which medicine to treat them with...
  7. ncbi The role of interferon therapy in hepatitis B
    W Graham E Cooksley
    Department of Medicine, University of Queensland, Royal Brisbane Hospital, Brisbane, Queensland, Australia
    MedGenMed 6:16. 2004
  8. ncbi Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection
    Carolyn A Lang
    Center for Diabetes and Endocrine Research, The University of Queensland, Queensland, Australia
    J Pain Symptom Manage 31:335-44. 2006
    ..These data demonstrate that symptoms are prevalent in treatment-naïve people with HCV and support the hypothesis that symptom clustering occurs...
  9. ncbi The treatment of hepatitis B e antigen-positive chronic hepatitis B with pegylated interferon
    Graham Cooksley
    Clinical Research Centre, Royal Brisbane Hospital Research Foundation, Brisbane, QLD, Australia
    J Hepatol 39:S143-5. 2003
  10. ncbi Does the addition of lamivudine to peginterferon alpha-2a sustain response rates in HBeAg-negative hepatitis B?
    Graham Cooksley
    University of Queensland, Royal Brisbane Hospital, Brisbane, Australia
    Nat Clin Pract Gastroenterol Hepatol 2:12-3. 2005
  11. ncbi Chronic hepatitis B: a critical appraisal of current approaches to therapy
    Robert P Perrillo
    Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Clin Gastroenterol Hepatol 4:233-48. 2006
    ..Expert opinions may differ from those of practicing hepatologists and gastroenterologists. We aimed to explore this issue further after a critical review of the literature...